博安生物：阿柏西普眼内注射溶液已申请在巴西上市

财中社08-05

8月5日，博安生物（06955）发布公告，公司的阿柏西普眼内注射溶液上市许可申请已在巴西国家卫生监督管理总局完成提交，拟用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。　　公告提到，阿柏西普眼内注射溶液是艾力雅®的生物类似药，已于2025年11月在中国获批上市。作为公司践行全球开发策略的重点品种之一，阿柏西普眼内注射溶液的海外布局正在加速拓展。（文章来源：财中社）

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2657544690?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-05 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657544690","market":"sh","top_or_hot":-1,"title":"博安生物：阿柏西普眼内注射溶液已申请在巴西上市","media":"财中社","content":"<div>\n<p>8月5日，博安生物（06955）发布公告，公司的阿柏西普眼内注射溶液上市许可申请已在巴西国家卫生监督管理总局完成提交，拟用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。　　公告提到，阿柏西普眼内注射溶液是艾力雅®的生物类似药，已于2025年11月在中国获批上市。作为公司践行全球开发策略的重点品种之一，阿柏西普眼内注射溶液的海外布局正在加速拓展。（文章来源：财中社）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608053832759832.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博安生物：阿柏西普眼内注射溶液已申请在巴西上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博安生物：阿柏西普眼内注射溶液已申请在巴西上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-05 20:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202608053832759832.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月5日，博安生物（06955）发布公告，公司的阿柏西普眼内注射溶液上市许可申请已在巴西国家卫生监督管理总局完成提交，拟用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。　　公告提到，阿柏西普眼内注射溶液是艾力雅®的生物类似药，已于2025年11月在中国获批上市。作为公司践行全球开发策略的重点品种之一，阿柏西普眼内注射溶液的海外布局正在加速拓展。（文章来源：财中社）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202608053832759832.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://finance.eastmoney.com/a/202608053832759832.html","article_id":"2657544690","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832759832.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2657544690","pubTimestamp":1785931860,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"8月5日，博安生物（06955）发布公告，公司的阿柏西普眼内注射溶液上市许可申请已在巴西国家卫生监督管理总局完成提交，拟用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。公告提到，阿柏西普眼内注射溶液是艾力雅?的生物类似药，已于2025年11月在中国获批上市。作为公司践行全球开发策略的重点品种之一，阿柏西普眼内注射溶液的海外布局正在加速拓展。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159100":"巴西","BK1161":"生物科技","IPOS":"Renaissance International IPO ETF","06955":"博安生物"},"translate_title":"Boan Bio: Aflibercept intraocular injection solution has applied for marketing in Brazil","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159100":1.5,"06955":1.5,"IPOS":1.5},"content_text":"8月5日，博安生物（06955）发布公告，公司的阿柏西普眼内注射溶液上市许可申请已在巴西国家卫生监督管理总局完成提交，拟用于治疗成人新生血管（湿性）年龄相关性黄斑变性和糖尿病性黄斑水肿。　　公告提到，阿柏西普眼内注射溶液是艾力雅®的生物类似药，已于2025年11月在中国获批上市。作为公司践行全球开发策略的重点品种之一，阿柏西普眼内注射溶液的海外布局正在加速拓展。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657544690","isCrawlerRequest":true}